NIPH Clinical Trials Search

UMIN ID: UMIN000002476

Registered date:10/09/2009

A multicenter phaseII study of FOLFIRI as FOLFOX refractory second-line chemotherapy for metastatic colorectal cancer with reduced starting dose of irinotecan in patients with honozygous for UGT1A1: (FLIGHT2)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedcolorectal cancer
Date of first enrollment2006/01/01
Target sample size50
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)On Day 1, patients treated with FOLFIRI therapy received a 2-hour intravenous infusion of CPT-11 (150 mg/m2) combined with 1-LV (200 mg/m2), followed by a rapid intravenous infusion of 5-FU (400 mg/m2), and then a 46-hour continuous infusion of 5-FU (2,400 mg/m2). This regimen comprised one course of therapy and was repeated once every 2 weeks. Cycles of treatment will be continued for this study until disease progression (PD) occurs. Patients will undergo UGT1A1 genotyping before starting to receive the protocol treatment. As recommended in the US prescribing information for Camptosar;, the starting dose of CPT-11 will be reduced to 100 mg/m2 in patients who are homozygous for the *28 allelic variant of UGT1A1 (further reduced to 75 mg/m2 in such patients aged 76-80 years). No dose adjustments will be made in patients who undergo UGT1A1 genotyping after starting to receive the protocol treatment.


Primary Outcome(1) response rate (2) incidence and severity of adverse events
Secondary Outcome(1) overall survival (OS), progression-free survival (PFS) (2) Evaluation of the causal relationship of each adverse event (3) To investigate genetic variation of UGT1A1 and correlation with the toxicities of CPT-11

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum80years-old
GenderMale and Female
Include criteria
Exclude criteria(1) Blood transfusion, administration of blood products, or hematopoietic (e.g., G-CSF) support within 7 days before enrollment. (2) A history of severe drug allergy. (3) Pleural effusion, ascites, or pericardial effusion requiring drainage. (4) Active (e.g., clinically significant) infection. (5) Confirmed or clinically suspected brain metastasis.*1 (6) Involvement of the central nervous system. (7) Presence of bone metastasis as the sole metastasis. (8) Any other concurrent malignancy, excluding metachronous malignancy that has been confirmed to have been cured.*2 (9) Uncontrolled hypercalcemia. (10) Uncontrolled hypertension (despite antihypertensive medication). (11) Uncontrolled diabetes mellitus. (12) Any significant electrocardiographic abnormality or clinically significant heart disease.*3 (13) Fresh gastrointestinal bleeding. (14) Intestinal paralysis or obstruction. (15) Diarrhea (watery stools).*4 (16) Positivity for HIV antibody. (17) Current treatment with atazanavir sulfate. (18) Current treatment with phenytoin, warfarin potassium, or flucytosine. (19) Pregnant or breast-feeding women, women of childbearing potential, women who wish to become pregnant, or men who wish to have a child with their female partners. (20) Current participation in any other clinical trial/study. (21) Any other condition that disqualifies the patient from the study in the opinion of the investigator.

Related Information


public contact
Name Mai Hatta
Address 65 Tsurumai Showa-ku Nagoya Japan
Telephone 052-744-2442
Affiliation Nagoya University Graduate School of Medicine Young Leaders'Program
scientific contact
Name Hideyuki Mishima
Address 1-1, Yazakokarimata, Nagakute, Aichi Japan
Telephone 0561-62-3311
Affiliation Aichi Medical University Cancer Center